Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block

Phase 4

Completed

Conditions: Fracture of Ankle

Interventions: Drug: Dexamethasone
Drug: Saline

First Posted Date: 2012-06-11

Last Posted Date: 2014-11-20

Lead Sponsor: Northwestern University

Target Recruit Count: 80

Registration Number: NCT01616173

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-06-08

Last Posted Date: 2024-10-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 45

Registration Number: NCT01615029

Efficacy and Safety of Single, Low-dose Dexamethasone in Patients After Total Knee Arthroplasty

Phase 4

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Dexamethasone

First Posted Date: 2012-06-06

Last Posted Date: 2013-05-27

Lead Sponsor: Tae Kyun Kim

Target Recruit Count: 291

Registration Number: NCT01612702

Locations: 🇰🇷
Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-Si, Gyeonggi-do, Korea, Republic of

Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery

Not Applicable

Completed

Conditions: Pain,
Edema,
Trismus

Interventions: Drug: Dexamethasone
Drug: Methylprednisolone

First Posted Date: 2012-05-23

Last Posted Date: 2012-05-23

Lead Sponsor: Federal University of the Valleys of Jequitinhonha and Mucuri

Target Recruit Count: 18

Registration Number: NCT01603498

Locations: 🇧🇷
Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Minas Gerais, Brazil

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Placebo
Drug: Dexamethasone
Drug: Bortezomib
Biological: Tabalumab

First Posted Date: 2012-05-18

Last Posted Date: 2019-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 220

Registration Number: NCT01602224

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Phase 3

Completed

Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions: Drug: Fosaprepitant Placebo
Drug: Fosaprepitant dimeglumine
Drug: Dexamethasone
Drug: Ondansetron
Drug: Dexamethasone Placebo
Drug: Ondansetron Placebo
Drug: Rescue Therapy

First Posted Date: 2012-05-09

Last Posted Date: 2018-09-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1015

Registration Number: NCT01594749

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-05-08

Last Posted Date: 2017-09-20

Lead Sponsor: Celgene

Target Recruit Count: 194

Registration Number: NCT01593410

Locations: 🇨🇳
307 Hospital of Chinese PLA, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
Chinese PLA General Hospital, Beijing, China

and more 9 locations

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma
Multiple Myeloma
Hodgkin Lymphoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Biological: Lirilumab
Biological: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2012-05-07

Last Posted Date: 2024-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 316

Registration Number: NCT01592370

Locations: 🇺🇸
Local Institution - 0007, Philadelphia, Pennsylvania, United States
🇺🇸
Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States
🇫🇷
Local Institution - 0043, Poitiers, Vienne, France

and more 38 locations

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215
Drug: lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-04-24

Last Posted Date: 2022-02-23

Lead Sponsor: Celgene

Target Recruit Count: 38

Registration Number: NCT01583283

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO

Phase 4

Completed

Conditions: Retinal Vein Occlusion

Interventions: Biological: RFB002
Drug: Dexamethasone

First Posted Date: 2012-04-18

Last Posted Date: 2016-05-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT01580020

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy